Skip to main content

Advertisement

SpringerLink
Log in

Maintenance chemotherapy in the management of epithelial ovarian cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

The fundamental goal of maintenance therapy of cancer is to extend a clinically meaningful survival endpoint (overall, symptom-free, progression-free) while at the same time not substantially interfering with a patient’s quality of life. Several phase 3 randomized trials in ovarian cancer involving different anti-neoplastics (e.g., paclitaxel, anti-angiogenic agents, olaparib) have revealed an improvement in progression-free survival with generally acceptable side effect profiles, and as a result represent in appropriately selected patients a rational therapeutic strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maughan, T. S., James, R. D., Kerr, D. J., et al. (2003). Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomized trial. Lancet, 361, 457–464.

    Article  CAS  PubMed  Google Scholar 

  2. Owonikoko, T. K., Ramalingam, S. S., & Belani, C. P. (2010). Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clinical Cancer Research, 11, 521–529.

    Google Scholar 

  3. Muss, H. B., Case, L. D., Richards, F., et al. (1991). Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. New England Journal of Medicine, 325, 1342–1348.

    Article  CAS  PubMed  Google Scholar 

  4. Katz, M. E., Schwartz, P. E., Kapp, D. S., et al. (1981). Epithelial carcinoma of the ovary: current strategies. Annals of Internal Medicine, 95, 98–111.

    Article  CAS  PubMed  Google Scholar 

  5. Young, P. C., Chabner, B. A., Hubbard, S. P., et al. (1978). Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. New England Journal of Medicine, 299, 1261–1266.

    Article  CAS  PubMed  Google Scholar 

  6. Greene, M. H., Boice, J. D., Jr., Greer, B. E., et al. (1982). Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized trials. New England Journal of Medicine, 307, 1416–1421.

    Article  CAS  PubMed  Google Scholar 

  7. Travis, L. B., Curtin, R. E., Boice, J. D., Jr., et al. (1996). Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Research, 56, 1564–1570.

    CAS  PubMed  Google Scholar 

  8. Lambert, H. E., Rustin, G. J., Gregory, W. M., et al. (1997). A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Annals of Oncology, 8, 327–333.

    Article  CAS  PubMed  Google Scholar 

  9. Bertelsen, K., Jakobsen, A., Stroyer, J., et al. (1993). A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecologic Oncology, 49, 30–36.

    Article  CAS  PubMed  Google Scholar 

  10. Hakes, T. B., Chalas, E., Hoskins, W. J., et al. (1992). Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecologic Oncology, 45, 284–289.

    Article  CAS  PubMed  Google Scholar 

  11. Rowinsky, E. K., & Donohower, R. C. (1995). Paclitaxel (taxol). New England Journal of Medicine, 332, 1004–1014.

    Article  CAS  PubMed  Google Scholar 

  12. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., et al. (1989). Taxol: a unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal Medicine, 111, 273–279.

    Article  CAS  PubMed  Google Scholar 

  13. Thigpen, J. T., Blessing, J. A., Ball, H., et al. (1994). Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 12, 1748–1753.

    CAS  PubMed  Google Scholar 

  14. Miller, K. D., Sweeney, C. J., & Sledge, G. W., Jr. (2001). Redefining the target: chemotherapeutics as antiangiogenics. Journal of Clinical Oncology, 19, 796–799.

    Google Scholar 

  15. Markman, H., Hakes, T., Barakat, R., et al. (1996). Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. Journal of Clinical Oncology, 14, 796–799.

    CAS  PubMed  Google Scholar 

  16. Rohl, J., Kushner, D., & Markman, M. (2001). Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecologic Oncology, 81, 201–205.

    Article  CAS  PubMed  Google Scholar 

  17. Von Gruenigen, V., Karlen, J. R., & Waggoner, S. E. (2003). A case of chronic paclitaxel administration in ovarian cancer. Gynecologic Oncology, 89, 532–535.

    Article  Google Scholar 

  18. Markman, M., Liu, P. Y., Wilczynski, S., et al. (2003). Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Journal of Clinical Oncology, 21, 2460–2465.

    Article  CAS  PubMed  Google Scholar 

  19. Markman, M., Liu, P., Wilcyznski, S., et al. (2009). Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecologic Oncology, 114, 195–198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Broglio, K. R., & Berry, D. A. (2009). Detecting an overall survival benefit that is derived from progression-free survival. Journal of the National Cancer Institute, 101, 1642–1649.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Pecorelli, S., Favalli, G., Gadducci, A., et al. (2009). Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 Protocol 1. Journal of Clinical Oncology, 27, 4642–4648.

    Article  CAS  PubMed  Google Scholar 

  22. Del Placido, S., Scambia, G., Di, V. G., et al. (2004). Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. Journal of Clinical Oncology, 22, 2635–2642.

    Article  PubMed  Google Scholar 

  23. Pfisterer, J., Weber, B., Reuss, A., et al. (2006). Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a Gynecologic Intergroup trial of the AGO-AOVAR and GINECO. Journal of the National Cancer Institute, 98, 1036–1045.

    Article  CAS  PubMed  Google Scholar 

  24. Bolis, G., Danese, S., Tateo, S., et al. (2006). Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. International Journal of Gynecological Cancer, 16(suppl 1), 74–78.

    Article  PubMed  Google Scholar 

  25. Alberts, D. S., Jiang, C., Liu, P. Y., et al. (2004). Long-term follow-up of a phase II trial of oral altretamine for consolidation of complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. International Journal of Gynecological Cancer, 14, 224–228.

    Article  CAS  PubMed  Google Scholar 

  26. Ferrara, N., & Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature, 438, 967–974.

    Article  CAS  PubMed  Google Scholar 

  27. Burger, R. A., Sill, M., Monk, B. J., et al. (2007). Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 25, 5165–5171.

    Article  CAS  PubMed  Google Scholar 

  28. Cannistra, S. A., Matulonis, U. A., Person, R. T., et al. (2007). Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. Journal of Clinical Oncology, 25, 5180–5186.

    Article  CAS  PubMed  Google Scholar 

  29. Burger, R. A., Brady, M. F., Bookman, M. A., et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365, 2473–2483.

    Article  CAS  PubMed  Google Scholar 

  30. Perren, T. J., Swart, A. M., Pfisterer, J., et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine, 365, 2484–2496.

    Article  CAS  PubMed  Google Scholar 

  31. Aghajanian, C., Blank, S. V., Goff, B. A., et al. (2012). OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of Clinical Oncology, 30, 2039–2045.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Pujade-Lauraine, E., Hilpert, F., Weber, B., et al. (2012). AURELIA: a randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology, 30 (suppl; LBA 5002).

  33. Burger, R. A. (2011). Overview of anti-angiogenic agents in development for ovarian cancer. 121:230–238.

  34. De Bois, A., Floquet, A., Kim, J. W., et al. (2013). Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: results of an international Intergroup trial (AGO-OVAR 16). Journal of Clinical Oncology, 31(suppl; LBA 5503).

  35. Hall, G. D., Brown, J. M., Coleman, R. E., et al. (2004). Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire Gynecology Group randomized phase III study. British Journal of Cancer, 91, 621–626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Alberts, D. S., Hannigan, E. V., Liu, P. Y., et al. (2006). Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecologic Oncology, 100, 133–138.

    Article  CAS  PubMed  Google Scholar 

  37. Berek, J., Taylor, P., McGuire, W., et al. (2009). Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. Journal of Clinical Oncology, 27, 418–425.

    Article  CAS  PubMed  Google Scholar 

  38. Sabbatini, P., Harter, P., Scambia, G., et al. (2013). Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study. Journal of Clinical Oncology, 31, 1554–1561.

    Article  CAS  PubMed  Google Scholar 

  39. Vergote, I. B., Jimeno, A., Joly, F., et al. (2014). Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platinum-based chemotherapy for ovarian carcinoma: a European Organization for Research and Treatment of Cancer—Gynaecological Cancer Group and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology, 32, 320–326.

    Article  CAS  PubMed  Google Scholar 

  40. Schilder, R. J., Sill, M. W., Chen, X., et al. (2005). Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. 11:5539–5548.

  41. Fong, P. C., Yap, T. A., Boss, D. S., et al. (2010). Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Journal of Clinical Oncology, 28, 2512–2519.

    Article  CAS  PubMed  Google Scholar 

  42. Ledermann, J., Harter, P., Gourley, C., et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine, 366, 1382–1392.

    Article  CAS  PubMed  Google Scholar 

  43. Farmer, H., McCabe, N., Lord, C. J., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917–921.

    Article  CAS  PubMed  Google Scholar 

  44. Hennessy, B. T. J., Timms, K., Carey, M. S., et al. (2010). Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from PARP inhibitors in ovarian cancer. Journal of Clinical Oncology, 28, 3570–3576.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Ledermann, J. A., Harter, P., Gourley, C., et al. (2013). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation. Journal of Clinical Oncology, 31(suppl; Abstract 5505).

Download references

Author information

Authors and Affiliations

  1. Cancer Treatment Centers of America, Philadelphia, PA, USA

    Maurie Markman

  2. College of Medicine, Drexel University, Philadelphia, PA, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurie Markman.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markman, M. Maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis Rev 34, 11–17 (2015). https://doi.org/10.1007/s10555-014-9537-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-014-9537-x

Keywords

Search

Navigation